We have observed
6 EP applications
Mark Frederic Paris Turner
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 23, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
HCV COMBINATION THERAPY
PROGNOSTIC METHOD FOR CHECKING EFFICACY OF MICRO RNA-122 INHIBITORS IN HCV+ PATIENTS
POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES
OLIGONUCLEOTIDE CONJUGATION PROCESS
IN VITRO TOXICITY SCREENING ASSAY